Source: Thailand Medical News Jan 16, 2020 5 years, 10 months, 4 weeks, 2 days, 9 hours, 44 minutes ago
Individuals with type 2
diabetes newly prescribed a sodium-glucose cotransporter-2 (
SGLT2)
inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study published online in the
Annals of Internal Medicine.
Dr Michael Fralick, M.D., Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues compared the rate of
gout between adults prescribed an
SGLT2 inhibitor and those prescribed a GLP1 receptor agonist in a population-based new-user cohort study; data were included for 295,907 adults. Patients with type 2
diabetes newly prescribed an
SGLT2 inhibitor were propensity score-matched to those newly prescribed a GLP1 agonist.
The medical researchers found that the incidence of
gout was lower among patients prescribed an
SGLT2 inhibitor versus those prescribed a GLP1 agonist (4.9 versus 7.8 events per 1,000 person-years), with a hazard ratio of 0.64 and a rate difference of −2.9 per 1,000 person-years.
Dr Fralick told
Thailand Medical News via a phone interview, "Future studies are necessary to confirm our findings, and if replicated,
SGLT2 inhibitors might be an effective class of medication for the prevention of
gout for patients with
diabetes or metabolic disorders.”
Two authors from the research team disclosed financial ties to the pharmaceutical industry.
Reference : Fralick M, Chen SK, Patorno E, et al. Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020; [Epub ahead of print 14 January 2020]. doi: https://doi.org/10.7326/M19-2610
